News Johnson & Johnson Swiss Exchange

Equities

JNJ

US4781601046

Market Closed - Swiss Exchange Other stock markets 10:06:39 01/03/2023 pm IST			5-day change	1st Jan Change
500 ^CHF	+194.12%		-.--%	-.--%

10:07am	J&J: applies to FDA for expanded indication for Prezcobix	CF
04/06	Global markets live: ASML, Intel, Microsoft, Tesla, J&J, Gitlab

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX	04:59pm	AQ
J&J: applies to FDA for expanded indication for Prezcobix	01:37pm	CF
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results	05/06	BU
Global markets live: ASML, Intel, Microsoft, Tesla, J&J, Gitlab	04/06
J&J: successful trial for Carvykti in multiple myeloma	04/06	CF
J&J: promising trial for Tecvayli in multiple myeloma	04/06	CF
Johnson & Johnson : showcases innovation and leadership in rheumatology at EULAR 2024 Congress	04/06	PU
Johnson & Johnson Ordered to Pay $260 Million In Talc Powder Case	04/06	MT
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors	04/06	AQ
J&J must pay $260 million in latest talc trial, Oregon jury says	04/06	RE
Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses	04/06	MT
Johnson & Johnson Announces Results from a Subgroup Analysis of the Phase 3 CARTITUDE-4 Study	04/06	CI
Johnson & Johnson Announces Data from the Phase 3 PERSEUS Study	04/06	CI
Johnson & Johnson Announces New Data from the Phase 2 PALOMA-2 Study Evaluating Subcutaneous (SC) Amivantamab Combined with Lazertinib as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer	04/06	CI
Johnson & Johnson Completes Acquisition of Shockwave Medical	03/06	AQ
Johnson & Johnson - First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration	03/06	AQ
Johnson & Johnson Announces Longer-Term Data from the Pivotal Phase 1/2 Majestec-1 Study of TECVAYLI	03/06	CI
J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO	03/06	RE
J&J-backed Rapport Therapeutics seeks to raise $144 mln in US IPO	03/06	RE
GSK blood cancer drug nearly halves risk of death in late-stage trial	02/06	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 11:00 pm IST